Stay updated on Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial
Sign up to get notified when there's something new on the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page.

Latest updates to the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page
- Check2 days agoChange DetectedThe record history now displays Revision: v3.5.4, replacing the previous v3.5.3. This reflects a minor metadata update to the page's revision history rather than a change to study content.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedA new revision, v3.5.3, was added to the record history, replacing the previous revision, v3.5.2. This indicates an update to the page's version metadata.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision history now includes a new version v3.5.2 and removes the older v3.5.0.SummaryDifference0.1%

- Check52 days agoChange DetectedNew revision entry added: v3.5.0. The previous revision v3.4.3 is listed as deleted.SummaryDifference0.1%

- Check66 days agoChange DetectedSite revision label updated from v3.4.2 to v3.4.3 in the page footer.SummaryDifference0.1%

- Check94 days agoChange DetectedRevision: v3.4.2 was added to the study record history, and Revision: v3.4.1 was removed. This is a minor update to release notes and does not alter the study information.SummaryDifference0.9%

Stay in the know with updates to Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page.